Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$143.15
1.901.35%
Dernière mise à jour: Nov 25, 9:41 AM
Comments
Loading...
Évaluations des analystes, objectifs de prix, prévision
Neurocrine Biosciences Inc a un objectif de cours consensuel de $173.25 basé sur les évaluations de 24 analystes. Le plus élevé est $219, publié par Oppenheimer le août 2, 2024. Le plus bas est $115, publié par BMO Capital le mai 6, 2025. Les 3 évaluations d’analystes les plus récentes ont été publiées par Morgan Stanley, JP Morgan et Truist Securities le novembre 11, 2025, novembre 3, 2025 et octobre 30, 2025, respectivement. Avec un objectif de cours moyen de $174.67 entre Morgan Stanley, JP Morgan et Truist Securities, il existe une variation implicite de 22.02% upside pour Neurocrine Biosciences Inc selon ces dernières évaluations d’analystes.
Sociétés d'analyse émettant des recommandations1
Morgan Stanley
JP Morgan
Truist Securities
Canaccord Genuity
Citigroup
1calculé à partir des notes des analystes
Notes d'analystes pour Neurocrine Biosciences
Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
11/11/2025 | 20.85% | Morgan Stanley | $178 → $173 | Maintains | Overweight | |||
11/03/2025 | 25.04% | JP Morgan | $171 → $179 | Maintains | Overweight | |||
10/30/2025 | 20.15% | Truist Securities | $165 → $172 | Reiterates | Buy → Buy | |||
10/29/2025 | 14.57% | Canaccord Genuity | $160 → $164 | Maintains | Buy | |||
10/29/2025 | 41.81% | Citigroup | $175 → $203 | Maintains | Buy | |||
10/29/2025 | 27.84% | Stifel | $174 → $183 | Maintains | Buy | |||
10/29/2025 | 11.77% | RBC Capital | $156 → $160 | Maintains | Outperform | |||
10/29/2025 | 25.04% | Piper Sandler | $175 → $179 | Maintains | Overweight | |||
10/29/2025 | 28.54% | Needham | $170 → $184 | Maintains | Buy | |||
10/21/2025 | 22.25% | Citigroup | → $175 | Initiates | → Buy | |||
10/20/2025 | 17.36% | Morgan Stanley | $163 → $168 | Maintains | Overweight | |||
10/09/2025 | 36.22% | UBS | $188 → $195 | Maintains | Buy | |||
09/22/2025 | 18.76% | Needham | $161 → $170 | Maintains | Buy | |||
09/05/2025 | 4.09% | RBC Capital | $144 → $149 | Maintains | Outperform | |||
09/05/2025 | 13.87% | Morgan Stanley | $158 → $163 | Maintains | Overweight | |||
08/06/2025 | 19.46% | JP Morgan | $183 → $171 | Maintains | Overweight | |||
08/01/2025 | 22.25% | Guggenheim | $165 → $175 | Maintains | Buy | |||
07/31/2025 | 0.59% | RBC Capital | $146 → $144 | Maintains | Outperform | |||
07/31/2025 | 21.55% | Stifel | $166 → $174 | Maintains | Buy | |||
07/31/2025 | 10.37% | Morgan Stanley | $150 → $158 | Maintains | Overweight | |||
07/31/2025 | 22.25% | Piper Sandler | $154 → $175 | Maintains | Overweight | |||
07/31/2025 | -1.5% | Wedbush | $137 → $141 | Maintains | Outperform | |||
07/22/2025 | 4.79% | Morgan Stanley | $148 → $150 | Maintains | Overweight | |||
07/21/2025 | 13.87% | Truist Securities | → $163 | Initiates | → Buy | |||
07/10/2025 | 27.14% | Goldman Sachs | → $182 | Initiates | → Buy | |||
07/09/2025 | 21.55% | UBS | $152 → $174 | Maintains | Buy | |||
06/02/2025 | 1.29% | RBC Capital | $145 → $145 | Reiterates | Outperform → Outperform | |||
05/06/2025 | 7.58% | Piper Sandler | $160 → $154 | Reiterates | Overweight → Overweight | |||
05/06/2025 | 1.29% | RBC Capital | $137 → $145 | Maintains | Outperform | |||
05/06/2025 | 15.26% | Guggenheim | $155 → $165 | Maintains | Buy | |||
05/06/2025 | -19.66% | BMO Capital | $96 → $115 | Maintains | Market Perform | |||
05/06/2025 | 6.18% | UBS | $137 → $152 | Maintains | Buy | |||
05/06/2025 | 11.77% | Canaccord Genuity | $158 → $160 | Maintains | Buy | |||
05/06/2025 | -2.9% | Needham | $138 → $139 | Maintains | Buy | |||
04/28/2025 | 10.37% | Canaccord Genuity | $163 → $158 | Maintains | Buy | |||
04/24/2025 | 29.24% | Evercore ISI Group | $190 → $185 | Maintains | Outperform | |||
04/22/2025 | 17.36% | HC Wainwright & Co. | $185 → $168 | Maintains | Buy | |||
04/15/2025 | -3.6% | Needham | → $138 | Upgrade | Hold → Buy | |||
04/14/2025 | -4.3% | RBC Capital | $138 → $137 | Upgrade | Sector Perform → Outperform | |||
04/04/2025 | -4.3% | UBS | $154 → $137 | Maintains | Buy | |||
03/07/2025 | 4.79% | Morgan Stanley | $185 → $150 | Assumes | → Overweight | |||
02/25/2025 | 27.84% | JP Morgan | $191 → $183 | Maintains | Overweight | |||
02/24/2025 | 29.24% | HC Wainwright & Co. | $185 → $185 | Reiterates | Buy → Buy | |||
02/21/2025 | 29.24% | HC Wainwright & Co. | $185 → $185 | Reiterates | Buy → Buy | |||
02/10/2025 | 13.87% | Guggenheim | $165 → $163 | Maintains | Buy | |||
02/10/2025 | 29.24% | HC Wainwright & Co. | $190 → $185 | Maintains | Buy | |||
02/07/2025 | 3.39% | RBC Capital | $154 → $148 | Maintains | Sector Perform | |||
02/07/2025 | 2.69% | Wedbush | $157 → $147 | Maintains | Outperform | |||
02/07/2025 | 13.87% | Canaccord Genuity | $172 → $163 | Maintains | Buy | |||
02/07/2025 | 29.24% | HC Wainwright & Co. | $190 → $185 | Maintains | Buy | |||
02/07/2025 | — | Needham | — | Reiterates | Hold → Hold | |||
02/07/2025 | 25.04% | B of A Securities | $184 → $179 | Maintains | Buy | |||
02/04/2025 | 28.54% | B of A Securities | $182 → $184 | Maintains | Buy | |||
02/04/2025 | 29.24% | Morgan Stanley | $170 → $185 | Maintains | Overweight | |||
01/30/2025 | 22.95% | UBS | $162 → $176 | Maintains | Buy | |||
01/08/2025 | 13.17% | UBS | $142 → $162 | Maintains | Buy | |||
12/23/2024 | 11.77% | Piper Sandler | $160 → $160 | Reiterates | Overweight → Overweight | |||
12/23/2024 | 15.26% | Barclays | $160 → $165 | Maintains | Overweight | |||
12/20/2024 | 27.14% | B of A Securities | $172 → $182 | Maintains | Buy | |||
12/20/2024 | — | Needham | — | Reiterates | Hold → Hold | |||
12/16/2024 | 3.39% | Wedbush | $148 → $148 | Reiterates | Outperform → Outperform | |||
12/16/2024 | 32.73% | HC Wainwright & Co. | $190 → $190 | Reiterates | Buy → Buy | |||
11/11/2024 | — | Needham | — | Reiterates | → Hold | |||
11/01/2024 | 32.73% | HC Wainwright & Co. | $190 → $190 | Reiterates | Buy → Buy | |||
10/31/2024 | — | Needham | — | Reiterates | → Hold | |||
10/30/2024 | — | Needham | — | Reiterates | → Hold | |||
10/29/2024 | — | Needham | — | Reiterates | → Hold | |||
10/17/2024 | -20.36% | BMO Capital | $128 → $114 | Maintains | Market Perform | |||
10/10/2024 | 8.28% | Raymond James | → $155 | Reinstates | → Outperform | |||
10/08/2024 | -7.09% | RBC Capital | $133 → $133 | Reiterates | Sector Perform → Sector Perform | |||
10/04/2024 | -7.09% | RBC Capital | $136 → $133 | Maintains | Sector Perform | |||
09/16/2024 | 8.28% | Cantor Fitzgerald | $155 → $155 | Reiterates | Overweight → Overweight | |||
09/09/2024 | 11.77% | Barclays | $180 → $160 | Maintains | Overweight | |||
08/29/2024 | 8.28% | Cantor Fitzgerald | $170 → $155 | Maintains | Overweight | |||
08/29/2024 | -10.58% | BMO Capital | $142 → $128 | Maintains | Market Perform | |||
08/29/2024 | 11.07% | Piper Sandler | $131 → $159 | Upgrade | Neutral → Overweight | |||
08/29/2024 | -4.99% | RBC Capital | $143 → $136 | Maintains | Sector Perform | |||
08/29/2024 | 32.73% | HC Wainwright & Co. | $190 → $190 | Reiterates | Buy → Buy | |||
08/29/2024 | — | Needham | — | Reiterates | → Hold | |||
08/19/2024 | 32.03% | Jefferies | $177 → $189 | Maintains | Buy | |||
08/07/2024 | 26.44% | JP Morgan | $173 → $181 | Maintains | Overweight | |||
08/05/2024 | 32.73% | HC Wainwright & Co. | $160 → $190 | Maintains | Buy | |||
08/02/2024 | -0.1% | RBC Capital | $136 → $143 | Maintains | Sector Perform | |||
08/02/2024 | 25.74% | Guggenheim | $170 → $180 | Maintains | Buy | |||
08/02/2024 | 10.37% | Citigroup | $150 → $158 | Maintains | Neutral | |||
08/02/2024 | 52.99% | Oppenheimer | $216 → $219 | Maintains | Outperform | |||
08/02/2024 | 25.74% | Barclays | $169 → $180 | Maintains | Overweight | |||
08/02/2024 | 25.74% | Baird | $157 → $180 | Maintains | Outperform | |||
08/01/2024 | — | Needham | — | Reiterates | → Hold | |||
07/25/2024 | 8.28% | Cantor Fitzgerald | $155 → $155 | Reiterates | Overweight → Overweight | |||
07/25/2024 | — | Needham | — | Reiterates | → Hold | |||
07/12/2024 | 18.76% | Morgan Stanley | $160 → $170 | Maintains | Overweight | |||
07/10/2024 | 20.85% | JP Morgan | $169 → $173 | Maintains | Overweight | |||
06/12/2024 | 11.77% | Morgan Stanley | $160 → $160 | Maintains | Overweight | |||
05/29/2024 | 6.18% | Wedbush | $152 → $152 | Reiterates | Outperform → Outperform | |||
05/28/2024 | 34.82% | UBS | $174 → $193 | Maintains | Buy | |||
05/14/2024 | 22.25% | Evercore ISI Group | → $175 | Initiates | → Outperform | |||
05/03/2024 | 4.79% | Citigroup | $140 → $150 | Maintains | Neutral | |||
05/02/2024 | 14.57% | Canaccord Genuity | $154 → $164 | Maintains | Buy | |||
05/02/2024 | 18.76% | Guggenheim | $164 → $170 | Maintains | Buy |
FAQ
Quel est le cours indicatif de l'action Neurocrine Biosciences (NBIX) ?
Le dernier objectif de prix pour Neurocrine Biosciences (NASDAQ:NBIX) a été rapporté par Morgan Stanley le novembre 11, 2025. Le cabinet d'analystes a fixé un objectif de prix pour $173.00 s'attendant à ce que NBIX se rise dans les 12 prochains mois (un possible changement de 20.85% upside). 62 cabinets d'analystes ont rapporté des notes au cours de la dernière année.
Quelle est la note d'analyste la plus récente pour Neurocrine Biosciences (NBIX) ?
La dernière note d'analyste pour Neurocrine Biosciences (NASDAQ:NBIX) a été fournie par Morgan Stanley, et Neurocrine Biosciences maintenu leur note overweight.
Quand a eu lieu la dernière mise à niveau pour Neurocrine Biosciences (NBIX) ?
La dernière amélioration pour Neurocrine Biosciences Inc a eu lieu le avril 15, 2025 lorsque Needham a augmenté leur objectif de prix à $138. Needham avait précédemment a hold pour Neurocrine Biosciences Inc.
Quand a eu lieu la dernière dégradation pour Neurocrine Biosciences (NBIX) ?
Il n'y a pas de dernière réduction pour Neurocrine Biosciences.
Quand la prochaine note d'analyste sera-t-elle publiée ou mise à jour pour Neurocrine Biosciences (NBIX) ?
Les analystes arrivent à des évaluations d'actions après avoir effectué des recherches approfondies, ce qui inclut l'examen des états financiers publics, la discussion avec les dirigeants et les clients de Neurocrine Biosciences, et l'écoute des conférences téléphoniques sur les résultats. La plupart des analystes font cela tous les trois mois, vous devriez donc obtenir 4 notes par entreprise par société chaque année. La dernière note pour Neurocrine Biosciences a été déposée le novembre 11, 2025, donc vous devriez vous attendre à ce que la prochaine note soit disponible vers novembre 11, 2026.
La note d'analyste pour Neurocrine Biosciences (NBIX) est-elle correcte ?
Bien que les évaluations soient subjectives et changeront, la dernière note de Neurocrine Biosciences (NBIX) était un maintenu avec un objectif de prix de $178.00 à $173.00. Le prix actuel de Neurocrine Biosciences (NBIX) est de $143.15, ce qui est out of la fourchette prédite par l'analyste.
Parcourir notes d'analystes et objectifs de cours sur toutes les actions.